Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Otsuka Holdings Co Ltd's Subsidiary to Form Joint Venture with Claris Lifesciences Limited and Mitsui & Co., Ltd.
Otsuka Holdings Co Ltd announced that its wholly owned subsidiary has decided to form a joint venture with Claris Lifesciences Limited and Mitsui & Co., Ltd., in 2013. The joint venture will be engaged in manufacturing and sales of basic transfusion and nutrition product. The subsidiary, Claris Lifesciences Limited and Mitsui & Co., Ltd. will hold 60%, 20% and 20% stakes in the joint venture, respectively.
Latest Developments for Claris Lifesciences Ltd
- Claris Lifesciences Ltd Receives ANDA Approval For Metroprolol Tartrate Injection In United States
- Claris Lifesciences Ltd Receives ANDA Approvals For Ondensetron Injection In US
- Claris Lifesciences Ltd Announces Demise Of Independent And Non Executive Chairman
- Claris Lifesciences Ltd In Talks With Otsuka Pharma To Sell Injectables Business-The Economic Times
Latest Key Developments in Pharmaceuticals
- Share this
- Link this
- Digg this
Follow Reuters